PCR

Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST

Wednesday, December 1, 2021 - 9:05pm

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.

Key Points: 
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe.
  • Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.

Global Molecular Diagnostics Market (2021 to 2031) - Featuring Abbott, Agilent Technologies and LungLife AI Among Others - ResearchAndMarkets.com

Wednesday, December 1, 2021 - 12:26pm

What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?

Key Points: 
  • What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
  • What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
  • Who are the leading players with significant offerings to the global molecular diagnostics market?
  • What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?

Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B

Wednesday, December 1, 2021 - 8:00am

Eurofins Technologies announces the launch of two RT-PCR assays to accurately diagnose respiratory diseases caused by SARS-CoV-2, Influenza virus or RSV.

Key Points: 
  • Eurofins Technologies announces the launch of two RT-PCR assays to accurately diagnose respiratory diseases caused by SARS-CoV-2, Influenza virus or RSV.
  • Since initial symptoms produced by these pathogens are indistinguishable, access to accurate and reliable tests will help clinicians improve patient care.
  • These new CE-marked multiplex kits have been specifically designed to detect and differentiate three viral infections in the same PCR run.
  • The RSV A, RSV B RT-PCR assay can differentiate between respiratory syncytial virus A and B.

Quidel Statement on the Omicron Variant

Tuesday, November 30, 2021 - 9:10pm

At Quidel, we continuously monitor the evolution and activity of COVID-19 variants in circulation, and the Omicron variant is no exception.

Key Points: 
  • At Quidel, we continuously monitor the evolution and activity of COVID-19 variants in circulation, and the Omicron variant is no exception.
  • Regarding our antigen assays, GISAID analysis shows a high likelihood that the Omicron variant is detectable by our immunoassays.
  • Of course, we are following up these analyses by testing live samples, and Quidel, like our industry peers, will know more in time.
  • While our studies are ongoing, the early data give us confidence that our American-made PCR and rapid antigen tests can detect COVID-19 caused by the Omicron variant.

Rapid PCR-Quality Detect Covid-19 Test Accurately Recognizes Omicron Variant (B.1.1.529) With Its Advanced Molecular Test Design

Tuesday, November 30, 2021 - 6:49pm

Detect, Inc. , a Connecticut-based health technology company, announced today that its PCR-quality, at-home rapid molecular Detect Covid-19 Test recognizes the Omicron (B.1.1.529) SARS CoV-2 variant.

Key Points: 
  • Detect, Inc. , a Connecticut-based health technology company, announced today that its PCR-quality, at-home rapid molecular Detect Covid-19 Test recognizes the Omicron (B.1.1.529) SARS CoV-2 variant.
  • Detects comprehensive bioinformatics analysis indicates that the Detect Covid-19 Test will identify Omicron as accurately as it recognizes the other major Covid-19 variants.
  • View the full release here: https://www.businesswire.com/news/home/20211130005985/en/
    The Detect Covid-19 Test identifies Omicron as accurately as it recognizes other major Covid-19 variants and will be available for purchase via Detect.com starting in mid-December.
  • Once available, it will be the lowest cost, PCR-quality test on the market among a new class of rapid molecular tests.

Global Green Packaging Market worth US$ 410.45 Bn by end of 2027, Says Coherent Market Insights

Tuesday, November 30, 2021 - 6:45pm

SEATTLE, Nov. 30, 2021 /PRNewswire/ --According to Coherent Market Insights, The global green packaging market is estimated to account for 410.45 Bn in terms of value and by the end of 2027 witnessing a CAGR of 6.71%.

Key Points: 
  • SEATTLE, Nov. 30, 2021 /PRNewswire/ --According to Coherent Market Insights, The global green packaging market is estimated to account for 410.45 Bn in terms of value and by the end of 2027 witnessing a CAGR of 6.71%.
  • Development and launch of sustainable packaging solutions is expected to propel growth of the global green packaging market over the forecast period.
  • Increasing adoption of recyclable packaging is expected to offer lucrative growth opportunities for players in the global green packaging market .
  • Major players operating in the global green packaging market are focused on launching new products to expand their product portfolio.

Global Green Packaging Market worth US$ 410.45 Bn by end of 2027, Says Coherent Market Insights

Tuesday, November 30, 2021 - 6:45pm

SEATTLE, Nov. 30, 2021 /PRNewswire/ --According to Coherent Market Insights, The global green packaging market is estimated to account for 410.45 Bn in terms of value and by the end of 2027 witnessing a CAGR of 6.71%.

Key Points: 
  • SEATTLE, Nov. 30, 2021 /PRNewswire/ --According to Coherent Market Insights, The global green packaging market is estimated to account for 410.45 Bn in terms of value and by the end of 2027 witnessing a CAGR of 6.71%.
  • Development and launch of sustainable packaging solutions is expected to propel growth of the global green packaging market over the forecast period.
  • Increasing adoption of recyclable packaging is expected to offer lucrative growth opportunities for players in the global green packaging market .
  • Major players operating in the global green packaging market are focused on launching new products to expand their product portfolio.

FDA Clears SeptiCyte® RAPID - The First One-Hour, Direct-from-Blood Sepsis Test

Tuesday, November 30, 2021 - 4:40pm

The cleared test is an aid in differentiating sepsis from infection-negative systemic inflammation in hospitalized patients suspected of sepsis.

Key Points: 
  • The cleared test is an aid in differentiating sepsis from infection-negative systemic inflammation in hospitalized patients suspected of sepsis.
  • SeptiCyte RAPID will be the first FDA cleared test to differentiate sepsis from non-infectious systemic inflammation to aid in a sepsis diagnosis within approximately one hour for patients suspected of sepsis.
  • As of November 2021, SeptiCyte RAPID has been FDA cleared for use in hospitalized patients suspected of sepsis.
  • SeptiCyte RAPID is a lab test for sepsis that combines SeptiCyte technology with the Biocartis' Idylla platform*, empowering clinicians to swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis; diagnosing bacterial sepsis, viral sepsis, or fungal infections.

GivingTuesday: NOVA Chemicals Expands Total COVID-19 Relief to US$1.25M with Additional Gifts

Tuesday, November 30, 2021 - 3:40pm

NOVA Chemicals Corporation (NOVA Chemicals) today announced an additional US$600,000 commitment in COVID-19-related supports across our operational regions, bringing the total amount given for pandemic relief to US$1.25M, as part of efforts to meaningfully give back to our neighbors and their communities.

Key Points: 
  • NOVA Chemicals Corporation (NOVA Chemicals) today announced an additional US$600,000 commitment in COVID-19-related supports across our operational regions, bringing the total amount given for pandemic relief to US$1.25M, as part of efforts to meaningfully give back to our neighbors and their communities.
  • NOVA Chemicals long-standing commitment to doing the right thing under the principles of Responsible Care is central to our operations.
  • NOVA Chemicals develops and manufactures chemicals and plastic resins that make everyday life healthier, easier and safer.
  • NOVA Chemicals, headquartered in Calgary, Alberta, Canada, is wholly owned ultimately by Mubadala Investment Company of the Emirate of Abu Dhabi, United Arab Emirates.

Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma

Tuesday, November 30, 2021 - 3:35pm

We believe this acquisition will solidify Todos Medicals position as a key player in the development and commercialization of 3CL protease-related products.

Key Points: 
  • We believe this acquisition will solidify Todos Medicals position as a key player in the development and commercialization of 3CL protease-related products.
  • Under the terms of the agreement, Todos Medical will own 60% of 3CL Sciences, and the shareholders of NLC Pharma will own 40% upon the execution of definitive agreements (the Closing) to acquire all intellectual property and assets related to 3CL protease biology-related products to which NLC Pharma has rights.
  • Todos Medical will assign its European licensing agreement T-Cell Hellas Protect S.A. to 3CL Sciences.
  • Tollovid's 3CL protease inhibition activity release criteria is at least twice as stringent as Tollovid Daily's 3CL protease inhibition release criteria.